THERAPY WITH JAK INHIBITORS AND THE RISK OF CARDIOVASCULAR EVENTS IN A DUTCH RHEUMATOID ARTHRITIS POPULATION

被引：0
|
作者：
Popa, C. [1 ,2 ]
Opdam, M. [1 ]
Den Broeder, N. [1 ]
Wientjes, M. [1 ]
Den Broeder, A. [1 ,2 ]
机构：
[1] Sint Maartensklin, Rheumatol, Ubbergen, Netherlands
[2] Radboudumc, Rheumatol, Nijmegen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Rheumatoid arthritis; Cardiovascular disease; Targeted synthetic; drugs;
D O I：
10.1136/annrheumdis-2023-eular.4033
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0221
引用
收藏
页码：145 / 146
页数：2
相关论文
共 50 条
  • [1] Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population
    Popa, Calin D.
    Opdam, Merel A. A.
    den Broeder, Nathan
    van Ballegooijen, Hanne
    Mulder, Kelly
    van de Wiel, Kayleigh M.
    van Herwaarden, Noortje
    Wientjes, Maike H. M.
    den Broeder, Alfons A.
    RHEUMATOLOGY, 2023, 63 (08) : 2142 - 2146
  • [2] Risk factors for cardiovascular events in a population with rheumatoid arthritis
    Ayas, SM
    Linklater, H
    Iveson, JM
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 145 - 146
  • [3] CARDIOVASCULAR EVENTS IN A HIGH RISK MEDICAID POPULATION WITH RHEUMATOID ARTHRITIS
    Shaya, F. T.
    Yan, X.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 165 - 165
  • [4] Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis
    Eun Ha Kang
    Katherine P. Liao
    Seoyoung C. Kim
    Current Rheumatology Reports, 2018, 20
  • [5] Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis
    Kang, Eun Ha
    Liao, Katherine P.
    Kim, Seoyoung C.
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (07)
  • [6] PREVALENCE OF RISK FACTORS FOR CARDIOVASCULAR EVENTS, MALIGNANCY OR THROMBOEMBOLIC EVENTS IN RHEUMATOID ARTHRITIS UNDER JAK INHIBITORS IN A REAL-LIFE MONOCENTRIC COHORT
    Giovannini, I.
    Agarinis, R.
    Cacioppo, S.
    Sacco, S.
    De Marchi, G.
    Di Poi, E.
    Zabotti, A.
    Quartuccio, L.
    De Vita, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1439 - 1440
  • [7] Risk of Cardiovascular Events, Malignancy, and Serious Infection Associated with JAK Inhibitors and TNF Inhibitors in Rheumatoid Arthritis or Ulcerative Colitis: A Nationwide Cohort Study
    Cho, Yongtai
    Yoon, Dongwon
    Khosrow-Khavar, Farzin
    Song, Minkyo
    Kim, Ju Hwan
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 9 - 9
  • [8] JAK inhibitors for rheumatoid arthritis
    Kubo, Satoshi
    Nakayamada, Shingo
    Tanaka, Yoshiya
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (04) : 333 - 344
  • [9] JAK inhibitors: risk of major adverse cardiovascular events
    Reactions Weekly, 2025, 2052 (1) : 8 - 8
  • [10] JAK Inhibitors for Rheumatoid Arthritis
    Marc D. Cohen
    Edward C. Keystone
    Current Treatment Options in Rheumatology, 2015, 1 (4) : 305 - 319
12345